› Product info › Blood Preparetions
- LIV-Gamma Inj. is used to reduce the risk of infection in individuals with poorly functioning immune systems such as those with hereditary immunodeficiency syndromes, chronic lymphocytic leukemia (CLL), and following bone marrow transplantation, to increase platelet counts in individuals with idiopathic thrombocytopenic purpura (ITP) and to prevent coronary artery aneurysms (weakening of the main artery in the heart) associated with Kawasaki syndrome.
1mL contains human immune globulin G 50mg.
LIV-Gamma Inj. is supplied in 500mg/10mL, 1,000mg/20mL, 2,500mg/50mL, 3,000mg/60mL
- ① Agammaglobulinemia, Hypogammaglobulinemia
- ② Combination therapy with antibiotics for severe infections
- ③ Idiopathic thrombocytopenicpurpura(ITP)
- ④ Guilian-Barre syndrome
- ⑤ Kawasaki disease
- ① Agammaglobulinemia, hypogammaglobulinemia, and combination therapy with antibiotics for severe infections after reconstitution: The dosage is 2,500-5,000mg (human immunoglobulin) as single dose for adult, 100-150mg/kg as single dose for children by intravenous instillation or injection. In case of intravenous injection, administer very slowly.
- ② Idiopathic thrombocytopenic purpura: The dosage is 200-400mg/kg daily, If the improvement in symptom is not shown after consecutive 5 days, administration should be discontinued.
- ③ Guillian-Barre syndrome (subacute demyelinating polyneuritis): The dosage is 400mg/kg once a day for consecutive 5 days.
- ④ Kawasaki disease (for the prevention of complication in coronary artery): The dosage is 400mg/kg once a day for consecutive 5 days.
- 1. Solvent/Detergent treatment of LIV-Gamma Inj. is very efficient virus inactivation process. This S/D treatment is especially efficent to HIV, HBV, HCV inactivation.
- 2. Manufacturing process of LIV-Gamma Inj. dose not denaturate proteins
- 3. Sorbitol which is able to protect virus, is not added in LIV-Gamma Inj.
- 4. LIV-Gamma Inj. is ready-to-use liquid formulation.